Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton, or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology‐specific a...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Rudolf A., Heymans, Stephane, Backs, Johannes, Carrier, Lucie, Coats, Andrew J.S., Dimmeler, Stefanie, Eschenhagen, Thomas, Filippatos, Gerasimos, Gepstein, Lior, Hulot, Jean‐Sebastien, Knöll, Ralph, Kupatt, Christian, Linke, Wolfgang A., Seidman, Christine E., Tocchetti, C. Gabriele, van der Velden, Jolanda, Walsh, Roddy, Seferovic, Petar M., Thum, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Hfa Position Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305112/
https://www.ncbi.nlm.nih.gov/pubmed/34969177
http://dx.doi.org/10.1002/ejhf.2414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305112/
https://www.ncbi.nlm.nih.gov/pubmed/34969177
http://dx.doi.org/10.1002/ejhf.2414

Ejemplares similares